Filter Results:
(1,243)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (927)
- Events (6)
- Multimedia (12)
- Faculty Publications (755)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (927)
- Events (6)
- Multimedia (12)
- Faculty Publications (755)
- November 1999
- Teaching Note
drugstore.com TN
By: Richard L. Nolan
Teaching Note for (9-300-036). View Details
- 06 Aug 2001
- Research & Ideas
Go Global—or No? Can You Make the Case?
Remember, we don't yet have the capability to serve the chemical and pharmaceutical industries here. There are still only 38 of us, and I estimate that building the support infrastructure we need just for domestic expansion could cost as... View Details
Keywords: by Walter Kuemmerle
- May 2025 (Revised June 2025)
- Supplement
Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (D)
By: Linda A. Hill and Lydia Begag
This fourth installment in the Pfizer Global Clinical Supply (GCS) transformation case series highlights how over a decade of cultural and digital evolution positioned GCS to meet unprecedented global challenges. In 2011, Michael Ku became the Vice President of GCS and... View Details
Keywords: Innovation Leadership; Technological Innovation; Leadership Development; Leadership Style; Research and Development; Science-Based Business; Transformation; Health Pandemics; AI and Machine Learning; Analytics and Data Science; Digital Transformation; Leading Change; Product Launch; Supply Chain; Organizational Change and Adaptation; Alignment; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; Asia; Europe; Latin America
Hill, Linda A., and Lydia Begag. "Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (D)." Harvard Business School Supplement 425-079, May 2025. (Revised June 2025.)
- April 2025
- Case
Radical Transformation at Bayer: Dynamic Shared Ownership
By: Boris Groysberg and Gamze Yucaoglu
In 2023, Bill Anderson became CEO of Bayer AG, a 160-year-old life sciences giant looking to strengthen its pharma pipeline, manage debt, and cut through bureaucracy. His bold response: Dynamic Shared Ownership (DSO), a radical model replacing traditional hierarchies... View Details
Keywords: Human Resources; Business Strategy; Alignment; Innovation and Management; Organizational Structure; Pharmaceutical Industry; Pharmaceutical Industry
Groysberg, Boris, and Gamze Yucaoglu. "Radical Transformation at Bayer: Dynamic Shared Ownership." Harvard Business School Case 425-061, April 2025.
- 2001
- Other Unpublished Work
Clusters of Innovation Initiative: San Diego
The study contains a conceptual framework for assessing the competitiveness of regional economies, an analysis of the San Diego region overall, as well as detailed assessments of two representative clusters—biotechnology/pharmaceuticals and communications. The report... View Details
Keywords: Clusters; Economics; Industry Clusters; Economy; Growth and Development; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; San Diego
Porter, Michael E. "Clusters of Innovation Initiative: San Diego." Council on Competitiveness, Washington, DC, May 2001. (Report.)
- 2014
- Working Paper
Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms
By: Prithwiraj Choudhury and Tarun Khanna
Since the 1990s, several Western firms have filed patents based on medicinal herbs from emerging markets, evoking protests from local stakeholders against 'bio-piracy'. We explore conditions under which firms and local stakeholders share rents from such patents. Our... View Details
Keywords: Rents From New Technology; Local Stakeholders; Herbal Patents; QCA; Fuzzy Set Analysis; Qualitative Case Studies; Plant-Based Agribusiness; Patents; Emerging Markets; Health Care and Treatment; Business and Stakeholder Relations; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Pharmaceutical Industry
Choudhury, Prithwiraj, and Tarun Khanna. "Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms." Harvard Business School Working Paper, No. 14-081, February 2014.
- September 1996
- Case
Food and Drug Administration: Business as Unusual at CDER
By: Steven C. Wheelwright and James Leonard
Wheelwright, Steven C., and James Leonard. "Food and Drug Administration: Business as Unusual at CDER." Harvard Business School Case 697-022, September 1996.
- November 1998
- Case
Wegmans Food Markets: Diabetes Counseling
By: Ray A. Goldberg, David E. Bell and Ann Leamon
Danny Wegman, president of Wegmans Food Markets, is trying to decide how to evaluate the success of a nutrition-counseling program for diabetics, and whether and how to expand the program beyond the two stores currently involved. Wegmans, with 57 stores and $2.3... View Details
Keywords: Performance Evaluation; Expansion; Programs; Human Needs; Financial Management; Health Care and Treatment; Nutrition; Consumer Behavior; Pharmaceutical Industry; Pharmaceutical Industry
Goldberg, Ray A., David E. Bell, and Ann Leamon. "Wegmans Food Markets: Diabetes Counseling." Harvard Business School Case 599-057, November 1998.
- 01 Sep 2012
- News
What’s the Big Idea?
international divisions. “Goldman Sachs in New York is different from Goldman Sachs in Asia,” he observes, adding that the same is true for conglomerates operating in industries as different as pharmaceuticals and aircraft engines.... View Details
- 04 Apr 2022
- Research & Ideas
Tech Hubs: How Software Brought Talent and Prosperity to New Cities
period. Software is penetrating other industries, Kerr notes. Take vaccines. Pharmaceutical companies’ speedy development of mRNA-based vaccines for COVID-19 required software, he notes. “Their capacity to bring a substantial software, AI... View Details
Keywords: by Rachel Layne
- 01 Aug 2001
- News
Cleveland Global Alumni Conference a Sold-Out Success
& Co., kicked off the first plenary session with a quick overview of factors contributing to the U.S. pharmaceutical industry's success in competing in the global market. Among other ad- vantages, Gilmartin cited the U.S. government's... View Details
- 18 Jul 2018
- Research & Ideas
No More General Tso's? A Threat to 'Knowledge Recombination'
pharmaceutical companies, which had been flying in scientists from China and India who, like Cohly, brought knowledge of native herbs. Some pharma companies were able to earn exemptions from the H1-B limits. Choudhury and Kim used this... View Details
- 26 Jun 2000
- Research & Ideas
What’s an Internet Business Model? Ask a Health Care Professional
out how to get into a clinical trial to try an experimental drug. For their part, physicians are often befuddled by difficult cases that don't respond to traditional therapies. And pharmaceutical companies, at the same time, are anxious... View Details
- 12 May 2009
- First Look
First Look: May 12, 2009
Case 809-026 An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access... View Details
Keywords: Martha Lagace
- 20 Nov 2006
- Research & Ideas
Open Source Science: A New Model for Innovation
problems that were posted? A: Innovations happen at the intersection of disciplines. People have talked about that a lot and I think we're providing some systematic evidence now with this study. Another example is that a pharmaceutical... View Details
Keywords: by Martha Lagace
- 22 Apr 2014
- First Look
First Look: April 22
constraints. Download working paper: https://www.hbs.edu/faculty/Pages/download.aspx?name=14-097.pdf The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories By:... View Details
Keywords: Sean Silverthorne
- 06 Jun 2017
- First Look
First Look at New Research and Ideas: June 6, 2017
regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars market entrants,... View Details
Keywords: Sean Silverthorne
- April 1984
- Supplement
Johnson & Johnson (A): Philosophy & Culture, James Burke, Video
By: Francis Aguilar
James Burke, chairman and CEO of Johnson & Johnson, discusses the company's philosophy and culture, with particular emphasis on the significance of the Credo. View Details
Keywords: Organizational Culture; Values and Beliefs; Mission and Purpose; Management Teams; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Aguilar, Francis. "Johnson & Johnson (A): Philosophy & Culture, James Burke, Video." Harvard Business School Video Supplement 884-525, April 1984.
- 30 Aug 2016
- First Look
August 30, 2016
our propositions using empirical data from a large pharmaceutical firm encompassing 407 architectural components and 1,157 dependencies between them. We show that different components occupy different positions in the IT architecture and... View Details
Keywords: Carmen Nobel
- 17 Sep 2001
- Research & Ideas
Why E-commerce Didn’t Die With the Fall of Webvan
induced about 12 percent of the pharmaceutical market to buy that way. Once that was done, it was comparatively straightforward to use the same inducements to persuade people who had Web access to do that over the Internet, saving the... View Details